(2R)-methyl-2-(benzyloxycarbonylamino)-3-methoxypropanoate | 209804-17-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R)-methyl-2-(benzyloxycarbonylamino)-3-methoxypropanoate
• 英文别名: D-Serine, O-methyl-N-[(phenylmethoxy)carbonyl]-, methyl ester；methyl (2R)-3-methoxy-2-(phenylmethoxycarbonylamino)propanoate
• CAS: 209804-17-1
• 化学式: C₁₃H₁₇NO₅
• 分子量: 267.282
• InChiKey: PUJUCYWWVNTBAM-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2R)-methyl-2-(benzyloxycarbonylamino)-3-methoxypropanoate 在 N-甲基吗啉 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 25.07h， 生成
  参考文献：
  名称：

  Synthesis and anticonvulsant activities of (R)-(O)-methylserine derivatives

  摘要：

  Efficient procedures for the synthesis of (R)-N-benzyl-2-amino-3-methoxypropionamide ((R)-3), 2-acetamido-3-methoxypropionic acid (4), and O-methylserine (5) are described beginning from (R)-Cbz-serine ((R)-7). The reactions proceeded with little or no racemization and permitted the synthesis of the potent anticonvulsant (R)N-benzyl-2-acetamido-3-methoxypropionamide ((R)-2). The anticonvulsant activities of 2-4 were determined revealing the surprising activity of (R)-2. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00403-0
• 作为产物：
  描述：

  甲醇 、 O1-benzyl O2-methyl (2R)-aziridine-1,2-dicarboxylate 在 三氟化硼乙醚 作用下， 以 氯仿 为溶剂， 生成 (2R)-methyl-2-(benzyloxycarbonylamino)-3-methoxypropanoate
  参考文献：
  名称：

  Discovery of DA-1229: A potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes

  摘要：

  A series of beta-amino amide containing substituted piperazine-2-one derivatives was synthesized and evaluated as inhibitors of dipeptidyl pepdidase-4 (DPP-4) for the treatment of type 2 diabetes. As results of intensive SAR study of the series, (R)-4-[(R)-3-amino-4-(2,4,5-trifluorophenyl)-butanoyl]-3-(t-butoxymethyl)-piperazin-2-one (DA-1229) displayed potent DPP-4 inhibition pattern in several animal models, was selected for clinical development. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.04.029

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF LACOSAMIDE<br/>[FR] PROCEDE DE PREPARATION DE LACOSAMIDE
  申请人：NATCO PHARMA LTD

  公开号：WO2011095995A1

  公开（公告）日：2011-08-11

  Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetamido-N-benzyl-3-methoxypropanamide) of formula (I). Present process utilizes high purity crystalline solids of formulae (XXXII) and (XIII) as key intermediates. Lacosamide is indicated for the adjunctive treatment of partial onset seizures in patients aged at least 17 years.

  本发明涉及一种改进的商业化过程，用于制备拉考酰胺（(R)-2-乙酰氨基-N-苄基-3-甲氧基丙酰胺）的化学式(I)。目前的工艺利用化学式(XXXII)和(XIII)的高纯度晶体固体作为关键中间体。拉考酰胺适用于至少17岁的患者的部分发作性癫痫的辅助治疗。
• PROCESS FOR THE PREPARATION OF LACOSAMIDE
  申请人：Muddasani Pulla Reddy

  公开号：US20130035508A1

  公开（公告）日：2013-02-07

  Present invention relates to an improved and commercial process for the preparation of lacosamide ((R)-2-acetami-do-N-benzyl-3-methoxypropanamide) of formula (I). Present process utilizes high purity crystalline solids of formulae (XXXII) and (XIII) as key intermediates. Lacosamide is indicated for the adjunctive treatment of partial onset seizures in patients aged at least 17 years.

  本发明涉及一种改进的商业化过程，用于制备拉考酰胺（(R)-2-乙酰胺基-N-苄基-3-甲氧基丙酰胺）的化学式(I)。目前的工艺利用化学式(XXXII)和(XIII)的高纯度结晶固体作为关键中间体。拉考酰胺适用于至少17岁的患者的部分发作性癫痫的辅助治疗。
• [EN] PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE LACOSAMIDE ET DE DÉRIVÉS INTERMÉDIAIRES DE N-BENZYL-PROPANAMIDE
  申请人：INDOCO REMEDIES LTD

  公开号：WO2012014226A1

  公开（公告）日：2012-02-02

  The present invention discloses novel process for the preparation of (2R)-2-acetamido-N- benzyl-3-methoxypropanamide of Formula I involving novel intermediates of Formula - XIX and Formula - XX.

  本发明公开了一种制备（2R）-2-乙酰氨基-N-苄基-3-甲氧基丙酰胺（化学式I）的新工艺，涉及到新中间体化合物XIX和XX的制备。
• [EN] GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES<br/>[FR] INHIBITEURS DE LA GLUCOSYLCÉRAMIDE SYNTHASE POUR LE TRAITEMENT DE MALADIES
  申请人：BIOMARIN PHARM INC

  公开号：WO2015042397A1

  公开（公告）日：2015-03-26

  Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

  本文描述了一种I式化合物，制备这种化合物的方法，含有这种化合物的药物组合物和药物，以及使用这种化合物治疗或预防与葡萄糖酰胺合成酶（GCS）相关的疾病或症状的方法。
• LACOSAMIDE INTERMEDIATE COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF
  申请人：ZHANG Xianyi

  公开号：US20120283466A1

  公开（公告）日：2012-11-08

  A new compound is provided, which is used for preparing lacosamide. A novel method for preparing lacosamide is also provided. During the reaction, iodomethane and silver oxide that are cost expensive are not used, nor a Pd-c catalyst is used, so the production cost is low, the raw materials and accessory materials are cheap and easily available, and the process is simple, so that industrial production is easy to realize; and moreover, the yield is high, and good economic efficiency can be achieved.

  提供了一种新的化合物，用于制备拉考酰胺。还提供了一种新颖的制备拉考酰胺的方法。在反应过程中，没有使用昂贵的碘甲烷和氧化银，也没有使用Pd-c催化剂，因此生产成本低，原材料和辅助材料廉价且易获得，工艺简单，易于实现工业化生产；此外，产率高，可以实现良好的经济效益。